Congenital hyperinsulinism due to compound heterozygous mutations in ABCC8 responsive to diazoxide therapy. [electronic resource]
- Journal of pediatric endocrinology & metabolism : JPEM May 2020
- 671-674 p. digital
Publication Type: Case Reports; Journal Article
2191-0251
10.1515/jpem-2019-0457 doi
Congenital Hyperinsulinism--drug therapy Diazoxide--therapeutic use Humans Infant, Newborn Male Sulfonylurea Receptors--genetics Treatment Outcome Vasodilator Agents--therapeutic use